Summary
47.14 -0.52(-1.09%)07/01/2024
Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals Inc (IONS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.14 | 5.27 | 21.68 | 7.28 | -10.84 | 14.75 | -27.25 | 453.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 47.14 | |
| Open | 47.78 | |
| High | 48.61 | |
| Low | 46.14 | |
| Volume | 2,169,458 | |
| Change | -0.55 | |
| Change % | -1.14 | |
| Avg Volume (20 Days) | 1,390,092 | |
| Volume/Avg Volume (20 Days) Ratio | 1.56 | |
| 52 Week Range | 35.95 - 54.44 | |
| Price vs 52 Week High | -13.41% | |
| Price vs 52 Week Low | 31.13% | |
| Range | -1.33 | |
| Gap Up/Down | 0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 6,876 | |
| EBIDTA | 128,645,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 25.7033 | |
| WallStreet Target Price | 51.31 | |
| Book Value | 3.7580 | |
| Earnings Per Share | -4.3710 | |
| EPS Estimate Current Quarter | -0.5200 | |
| EPS Estimate Next Quarter | -0.1400 | |
| EPS Estimate Current Year | -1.3600 | |
| EPS Estimate Next Year | -1.8800 | |
| Diluted EPS (TTM) | -4.3710 | |
| Revenues | ||
| Profit Marging | -0.9304 | |
| Operating Marging (TTM) | -0.3319 | |
| Return on asset (TTM) | -0.0498 | |
| Return on equity (TTM) | -0.5765 | |
| Revenue TTM | 660,731,008 | |
| Revenue per share TTM | 4.6960 | |
| Quarterly Revenue Growth (YOY) | -0.1690 | |
| Quarterly Earnings Growth (YOY) | -0.4370 | |
| Gross Profit (TTM) | 182,240,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 90.9091 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.8439 | |
| Revenue Enterprise Value | 5.2686 | |
| EBITDA Enterprise Value | 42.2015 | |
| Shares | ||
| Shares Outstanding | 141,210,000 | |
| Shares Float | 140,001,257 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.81 | |
| Institutions (%) | 86.95 | |
06/26 14:01 EST - zacks.com
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
06/25 07:30 EST - zacks.com
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
06/25 06:55 EST - prnewswire.com
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
– Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 – CARLSBAD, Calif. , June 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for olezarsen, an investigational RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS).
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
– Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 – CARLSBAD, Calif. , June 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for olezarsen, an investigational RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS).
06/19 13:15 EST - zacks.com
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
06/18 07:00 EST - prnewswire.com
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD, Calif. , June 18, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd.
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD, Calif. , June 18, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd.
06/17 16:09 EST - prnewswire.com
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
CARLSBAD, Calif. , June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
CARLSBAD, Calif. , June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.
05/31 07:00 EST - prnewswire.com
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time In first-of-its-kind prospective analysis, patients switching from prior prophylactic treatment to donidalorsen experienced further reductions in mean monthly HAE attack rates from baseline Donidalorsen demonstrated a favorable safety and tolerability profile across all cohorts Data to be presented today at EAACI Congress 2024 Ionis to host webcast on Friday, May 31 at 8:00am ET CARLSBAD, Calif. , May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE) demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of >90% with one year of treatment for both monthly or every two-month dosing.
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time In first-of-its-kind prospective analysis, patients switching from prior prophylactic treatment to donidalorsen experienced further reductions in mean monthly HAE attack rates from baseline Donidalorsen demonstrated a favorable safety and tolerability profile across all cohorts Data to be presented today at EAACI Congress 2024 Ionis to host webcast on Friday, May 31 at 8:00am ET CARLSBAD, Calif. , May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE) demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of >90% with one year of treatment for both monthly or every two-month dosing.
05/28 16:39 EST - seekingalpha.com
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
Ionis Pharmaceuticals' Q1 2024 earnings showed a loss of $143m, a larger loss than the $87m in the previous year. The company has a healthy cash balance of $2.2bn and expects revenues of +$575m in 2024, albeit with further heavy losses. Ionis has several upcoming pipeline opportunities, including the potential approval of pelacarsen and label expansions for Wainua and Olezarsen.
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
Ionis Pharmaceuticals' Q1 2024 earnings showed a loss of $143m, a larger loss than the $87m in the previous year. The company has a healthy cash balance of $2.2bn and expects revenues of +$575m in 2024, albeit with further heavy losses. Ionis has several upcoming pipeline opportunities, including the potential approval of pelacarsen and label expansions for Wainua and Olezarsen.
05/28 07:00 EST - prnewswire.com
Ionis to hold donidalorsen Phase 3 data webcast
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif.
Ionis to hold donidalorsen Phase 3 data webcast
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif.
05/23 07:00 EST - prnewswire.com
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30.
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30.
05/17 11:11 EST - zacks.com
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
05/16 14:07 EST - marketwatch.com
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Sclerosis, or ALS, after a disappointing trial.
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Sclerosis, or ALS, after a disappointing trial.
05/16 07:41 EST - reuters.com
Biogen, Ionis to discontinue development of ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
Biogen, Ionis to discontinue development of ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
05/16 07:30 EST - prnewswire.com
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CARLSBAD, Calif. and CAMBRIDGE, Mass.
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative condition CARLSBAD, Calif. and CAMBRIDGE, Mass.
05/16 07:00 EST - prnewswire.com
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivotal trial Detailed ION582 data to be presented at upcoming medical meeting CARLSBAD, Calif. , May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome.
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivotal trial Detailed ION582 data to be presented at upcoming medical meeting CARLSBAD, Calif. , May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome.
05/15 07:05 EST - prnewswire.com
Ionis to host 2024 virtual Annual Meeting of Stockholders
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024.
Ionis to host 2024 virtual Annual Meeting of Stockholders
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024.
05/09 06:30 EST - investorplace.com
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Here's a question for you: What determines the value of a drug? Is it the number of lives it saves or how much it costs to make?
05/08 11:42 EST - zacks.com
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
05/07 17:39 EST - seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2024 Results Conference Call May 7, 2024 11:30 AM ET Company Participants Wade Walke - SVP of IR Brett Monia - CEO Kyle Jenne - Chief Global Product Strategy Officer Beth Hougen - CFO Richard Geary - Chief Development Officer Eric Swayze - EVP of Research Eugene Schneider - Chief Clinical Development Officer Jonathan Birchall - Chief Commercial Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities Gary Nachman - Raymond James Jessica Fye - JPMorgan Joseph Stringer - Needham & Company Jason Gerberry - Bank of America Yanan Zhu - Wells Fargo Luca Issi - RBC David Lebowitz - Citi Kostas Biliouris - BMO Operator Good morning. And welcome to Ionis' First Quarter 2024 Financial Results Conference Call.
Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2024 Results Conference Call May 7, 2024 11:30 AM ET Company Participants Wade Walke - SVP of IR Brett Monia - CEO Kyle Jenne - Chief Global Product Strategy Officer Beth Hougen - CFO Richard Geary - Chief Development Officer Eric Swayze - EVP of Research Eugene Schneider - Chief Clinical Development Officer Jonathan Birchall - Chief Commercial Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities Gary Nachman - Raymond James Jessica Fye - JPMorgan Joseph Stringer - Needham & Company Jason Gerberry - Bank of America Yanan Zhu - Wells Fargo Luca Issi - RBC David Lebowitz - Citi Kostas Biliouris - BMO Operator Good morning. And welcome to Ionis' First Quarter 2024 Financial Results Conference Call.
05/07 10:36 EST - zacks.com
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.